Blueprint Medicines (NASDAQ:BPMC) PT Raised to $75.00

Blueprint Medicines (NASDAQ:BPMC – Get Free Report) had its price target boosted by equities research analysts at Barclays from $70.00 to $75.00 in a report released on Friday, Benzinga reports. The firm presently has an “equal weight” rating on the biotechnology company’s stock. Barclays‘s price target would suggest a potential downside of 30.23% from the […]

Related Keywords

United States ,Jeffreyw Albers ,Christopherk Murray , ,Associates Corp ,Blueprint Medicines Corporation ,Financial Services Group Inc ,Citigroup ,Blueprint Medicines Company Profile ,Nasdaq ,Needham Company ,Mirae Asset Global Investments Co ,Barclays ,Principal Financial Group Inc ,Blueprint Medicines ,Get Free Report ,Director Jeffrey ,Asset Global Investments ,Financial Group ,Services Group ,Medicines Corporation ,Blueprint Medicines Daily ,Nasdaq Bpmc ,Bpmc ,Medical ,Boost Price Target ,Barclays Plc ,